School of Pharmacy & Medical Sciences, Gold Coast campus, Griffith University, Brisbane, QLD-4222, Australia.
Menzies Health Institute Queensland (MHIQ), Gold Coast Campus, Griffith University, Brisbane, QLD-4215, Australia.
Oncol Res. 2024 Sep 18;32(10):1543-1564. doi: 10.32604/or.2024.043987. eCollection 2024.
The advent of RNA therapy, particularly through the development of mRNA cancer vaccines, has ushered in a new era in the field of oncology. This article provides a concise overview of the key principles, recent advancements, and potential implications of mRNA cancer vaccines as a groundbreaking modality in cancer treatment. mRNA cancer vaccines represent a revolutionary approach to combatting cancer by leveraging the body's innate immune system. These vaccines are designed to deliver specific mRNA sequences encoding cancer-associated antigens, prompting the immune system to recognize and mount a targeted response against malignant cells. This personalized and adaptive nature of mRNA vaccines holds immense potential for addressing the heterogeneity of cancer and tailoring treatments to individual patients. Recent breakthroughs in the development of mRNA vaccines, exemplified by the success of COVID-19 vaccines, have accelerated their application in oncology. The mRNA platform's versatility allows for the rapid adaptation of vaccine candidates to various cancer types, presenting an agile and promising avenue for therapeutic intervention. Clinical trials of mRNA cancer vaccines have demonstrated encouraging results in terms of safety, immunogenicity, and efficacy. Pioneering candidates, such as BioNTech's BNT111 and Moderna's mRNA-4157, have exhibited promising outcomes in targeting melanoma and solid tumors, respectively. These successes underscore the potential of mRNA vaccines to elicit robust and durable anti-cancer immune responses. While the field holds great promise, challenges such as manufacturing complexities and cost considerations need to be addressed for widespread adoption. The development of scalable and cost-effective manufacturing processes, along with ongoing clinical research, will be pivotal in realizing the full potential of mRNA cancer vaccines. Overall, mRNA cancer vaccines represent a cutting-edge therapeutic approach that holds the promise of transforming cancer treatment. As research progresses, addressing challenges and refining manufacturing processes will be crucial in advancing these vaccines from clinical trials to mainstream oncology practice, offering new hope for patients in the fight against cancer.
RNA 疗法的出现，特别是通过 mRNA 癌症疫苗的发展，为肿瘤学领域带来了一个新时代。本文简要概述了 mRNA 癌症疫苗作为癌症治疗中一种开创性的模式的关键原则、最新进展和潜在影响。mRNA 癌症疫苗通过利用人体固有免疫系统，代表了一种对抗癌症的革命性方法。这些疫苗旨在递送特定的编码癌症相关抗原的 mRNA 序列，促使免疫系统识别并针对恶性细胞发起靶向反应。mRNA 疫苗的这种个性化和适应性特征为解决癌症的异质性并为个体患者量身定制治疗方案提供了巨大的潜力。mRNA 疫苗的开发最近取得了突破，如 COVID-19 疫苗的成功，加速了它们在肿瘤学中的应用。mRNA 平台的多功能性允许快速适应各种癌症类型的疫苗候选物，为治疗干预提供了灵活而有前途的途径。mRNA 癌症疫苗的临床试验在安全性、免疫原性和疗效方面取得了令人鼓舞的结果。先驱候选物，如 BioNTech 的 BNT111 和 Moderna 的 mRNA-4157，分别在针对黑色素瘤和实体瘤方面表现出了有前景的结果。这些成功突显了 mRNA 疫苗引发强大和持久的抗癌免疫反应的潜力。尽管该领域前景广阔，但需要解决制造复杂性和成本考虑等挑战，才能广泛采用。可扩展和具有成本效益的制造工艺的开发以及正在进行的临床研究将是实现 mRNA 癌症疫苗全部潜力的关键。总体而言，mRNA 癌症疫苗代表了一种有前途的治疗方法，有望改变癌症治疗。随着研究的进展，解决挑战和改进制造工艺将是将这些疫苗从临床试验推进到主流肿瘤学实践的关键，为癌症患者的治疗带来新的希望。
